3
H index
0
i10 index
19
Citations
Office of Health Economics | 3 H index 0 i10 index 19 Citations RESEARCH PRODUCTION: 4 Articles 15 Papers RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Grace Hampson. | Is cited by: | Cites to: |
Working Papers Series with more than one paper published | # docs |
---|---|
Research Papers / Office of Health Economics | 7 |
Briefings / Office of Health Economics | 4 |
Consulting Reports / Office of Health Economics | 4 |
Year | Title of citing document | |
---|---|---|
2020 | Regenerative medicine regulatory policies: A systematic review and international comparison. (2020). Toumi, Mondher ; Borislav, Borisov ; Dabbous, Monique ; Hanna, Eve ; Qiu, Tingting. In: Health Policy. RePEc:eee:hepoli:v:124:y:2020:i:7:p:701-713. Full description at Econpapers || Download paper | |
2020 | Complexity Stage Model of the Medical Device Development Based on Economic Evaluation—MedDee. (2020). Peter, Luka ; Mareova, Petra ; Kua, Kamil ; Klimova, Blanka ; Mohelska, Hana ; Augustnek, Martin ; Penhaker, Marek ; Ren, Luka ; Honegr, Jan. In: Sustainability. RePEc:gam:jsusta:v:12:y:2020:i:5:p:1755-:d:325509. Full description at Econpapers || Download paper | |
2020 | Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review. (2020). Ghabri, Salah ; Bousquet, Philippe Jean ; Bouee-Benhamiche, Elsa. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:4:d:10.1007_s40258-020-00562-z. Full description at Econpapers || Download paper | |
2020 | Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment. (2020). Gonalves, Elisabete. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:21:y:2020:i:3:d:10.1007_s10198-019-01147-x. Full description at Econpapers || Download paper | |
2020 | HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. (2020). Shah, Koonal ; Graf von der Schulenburg, Johann ; Shen, Jie ; Durand-Zaleski, Isabelle ; Ratcliffe, Mark ; Coyle, Doug ; Pemberton-Whiteley, Zack ; Palmer, Stephen ; Moutie, Anne-Sophie ; Meunier, Aurelie ; Longworth, Louise ; Greiner, Wolfgang ; Zhao, Kun ; Garrison, Louis ; Sproule, Doug ; Farrington, Jasmine. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:21:y:2020:i:9:d:10.1007_s10198-020-01212-w. Full description at Econpapers || Download 2020 | Integrative Review of Managed Entry Agreements: Chances and Limitations. (2020). Pomorski, Maciej ; Vassalo, Carlos ; Azevedo, Pamela Santos ; Guerra-Junior, Augusto Afonso ; Lipinska, Aneta ; Hauegen, Renata Curi ; Gargano, Ludmila Peres ; Alvares-Teodoro, Juliana ; Gulbinovic, Jolanta ; Pippo, Tomas ; Godman, Brian ; de Assis, Francisco ; Kwon, Hye-Young ; Iunes, Roberto ; Dias, Carolina Zampirolli ; Araujo, Vania Eloisa ; Garattini, Livio ; Zuppo, Isabella Figueiredo ; Selke, Gisbert W ; Borin, Marcus Carvalho ; Canuto, Vania Cristina ; Voncina, Luka ; Pereira, Andre Luiz ; Ortiz, Carla Hernandez ; Gomez, Carolina ; Ribeiro-Junior, Nelio Gomes ; Gambogi, Rosana ; Marquez, Sergio ; Neiva, Lais Lessa ; Furst, Jurij ; Simoens, Steven ; Cazarim, Maurilio Souza ; McClure, |
2020 | Recalibrating Health Technology Assessment Methods for Cell and Gene Therapies. (2020). Hackshaw, Allan ; Naci, Huseyin ; Angelis, Aris. In: PharmacoEconomics. RePEc:spr:pharme:v:38:y:2020:i:12:d:10.1007_s40273-020-00956-w. Full description at Econpapers || Download paper | |
2020 | Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review. (2020). Catchpole, Paul ; Barrett, Victoria. In: PharmacoEconomics. RePEc:spr:pharme:v:38:y:2020:i:9:d:10.1007_s40273-020-00918-2. Full description at Econpapers || Download paper | |
2020 | Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review. (2020). Catchpole, Paul ; Barrett, Victoria. In: PharmacoEconomics. RePEc:spr:pharme:v:38:y:2020:i:9:d:10.1007_s40273-020-00918-2. Full description at Econpapers || Download paper |
Year | Title | Type | Cited |
---|---|---|---|
2016 | New Age Decision Making in HTA: Is It Applicable in Asia? In: Briefings. [Full Text][Citation analysis] | paper | 0 |
2017 | Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies In: Briefings. [Full Text][Citation analysis] | paper | 0 |
2017 | How can HTA meet the needs of health system and government decision makers? In: Briefings. [Full Text][Citation analysis] | paper | 0 |
2017 | Transferability of HTA In: Briefings. [Full Text][Citation analysis] | paper | 0 |
2016 | Four Case Studies to Explore the Added Value of Oxford AHSN In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2017 | Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose? In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
2017 | Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
2019 | Public Preferences for Health Gains and Cures: A Discrete Choice Experiment In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
2015 | Dementia: The R&D Landscape In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
2016 | A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications In: Research Papers. [Full Text][Citation analysis] | paper | 3 |
2016 | Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
2018 | Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open. [Full Text][Citation analysis] This paper has another version. Agregated cites: 0 | article | |
2017 | Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value In: Research Papers. [Full Text][Citation analysis] | paper | 1 |
2017 | Macro Evaluation of the NIHR Oxford Biomedical Research Centre In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
2018 | Real World Evidence for Coverage Decisions: Opportunities and Challenges In: Research Papers. [Full Text][Citation analysis] | paper | 4 |
2018 | Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
2017 | What Determines the Health Care Expenditure of High Income Countries? A Dynamic Estimation In: Applied Economics and Finance. [Full Text][Citation analysis] | article | 0 |
2017 | A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 3 |
2019 | Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 5 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated November, 2 2021. Contact: CitEc Team